skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

3655

Biologics: Targets & Therapy

(402,183) Views

Editor in Chief Professor Doris Mangiaracina Benbrook

1177-5475

Cetuximab in the management of colorectal cancer
Heinz-Josef Lenz

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
Ruben A Mesa

Editorial: Evidence is steadily accumulating that ... || FREE PAPER ||
Sanjay Awasthi

Biological targets for isatin and its analogues: Implications for therapy
Alexei Medvedev, Olga Buneeva, Vivette Glover

Dishing the dirt on asthma: What we can learn from poor hygiene
Catherine de Lara, Alistair Noble

The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT
Andreas Koster, Karl-Georg Fischer, Sebastian Harder, Fritz Mertzlufft

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
Giovanni Martinelli, Ilaria Iacobucci, Simona Soverini, Francesca Palandri, Fausto Castagnetti et al

Drug focus: adalimumab in the treatment of moderate to severe psoriasis
Gino A Vena

Infliximab in the treatment of ankylosing spondylitis
Rebecca Grainger, Andrew A Harrison

Advanced ovarian cancer: Vaccination site draining lymph node as target of immuno-modulative adjuvants in autologous cancer vaccine
Eduardo Lasalvia-Prisco, Emilio Garcia-Giralt, Silvia Cucchi, Jesús Vázquez, Leonard Robinson, et al

Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma
Biree Andemariam, John P Leonard

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed